ESPR Overview
Upcoming Projects (ESPR)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ESPR)
-
Two Week Delay: NEXLETOL (bempedoic acid) Survey
Ticker: ESPR
Executed On: Nov 21, 2022 at 04:18 PM EST -
A Second Look: Digging into the use of Esperion's NEXLETOL (bempedoic acid) in atherosclerotic cardiovascular disease (ASCVD)
Ticker: ESPR
Executed On: Sep 26, 2022 at 09:00 AM EDT -
Digging into the use of Esperion's NEXLETOL (bempedoic acid) in atherosclerotic cardiovascular disease (ASCVD)
Ticker: ESPR
Executed On: Sep 21, 2022 at 05:30 PM EDT
Upcoming & Overdue Catalysts (ESPR)
-
Following CLEAR CVOT, Esperion Therapeutics (ESPR) to submit New Drug Application to FDA for reduction of risk of cardiovascular disease, MAA to EMA, by 2022
Ticker: ESPR
Future Window: Jan 01, 2022 - Dec 31, 2022
Overdue
Occurred Catalysts (ESPR)
-
Top-Line Results Released from Esperion's ($ESPR) Final Pivotal Phase 3 Study of Bempedoic Acid
Ticker: ESPR
Occurred on: Oct 28, 2018 -
MRK's CETP CV outcomes for hypercholesterolemia expected in Q1 2017
Tickers: MRK, AMGN, ESPR
Occurred on: Jun 27, 2017 -
Esperion (ESPR) to Announce Clinical Development and Regulatory Plans for Bempedoic Acid + Ezetimibe (BA+EZ) in H1 2017
Ticker: ESPR
Occurred on: Mar 07, 2017 -
Esperion Therapeutics (ESPR) Announces Phase 2 Data Evaluating Bempedoic Acid Added to Atorvastatin in Hypercholesterolemia
Tickers: ESPR, PFE
Occurred on: Oct 13, 2016
Strategic Initiatives (ESPR)
-
Don’t see a strategic initiative related to the company you care about? Create your own!